KLOW is a commercial name for a vial holding four peptides at once: GHK-Cu, BPC-157, TB-500 and KPV. It is sold premixed, which changes the dosage question in a way single-compound pages never face. In a premixed vial the seller's ratio, not the buyer's arithmetic, decides how much of each peptide a given volume contains.
This page reports what sellers' own labels state and what follows arithmetically from them. It recommends nothing. Our peptide stacks page covers what a blend name means and what has been tested; this page covers the numbers.
What the labels say
| Seller | GHK-Cu | BPC-157 | TB-500 | KPV | Total | Name used |
|---|---|---|---|---|---|---|
| Prime Labs (opened 17 Sep 2026) | 50 mg | 10 mg | 10 mg | 10 mg | 80 mg | KLOW |
| Medica Depot (opened 17 Sep 2026) | 50 mg | 10 mg | 10 mg | 10 mg | 80 mg | Klow |
| BHR Center, a clinic (opened 17 Sep 2026) | 5 mg | 5 mg | 5 mg | 10 mg | 25 mg | Quad Healing Blend |
The first two agree exactly. The third sells the same four molecules in a different proportion and under a different name, describing its "carefully calibrated dosing ratios (5/5/10/5mg)" as reflecting "years of clinical experience".
Two other details from the same pages are worth recording. One vendor lists the product only by total — "80 MG" as the selected "Dosage" option — with the split in the description. Another lists a 3 mL vial, which is the glass, not a concentration: no seller opened here states a reconstitution volume, so the milligrams per millilitre of a prepared vial are set by whoever prepares it.
The ratio is the dose
In the 80 mg vial the four peptides sit at 5 : 1 : 1 : 1, GHK-Cu first. GHK-Cu is 62.5% of the peptide mass in the vial; the other three are 12.5% each.
That has a consequence a per-compound page never has to state: choosing a figure for one peptide fixes the other three. The table below works it through for two stated BPC-157 amounts, using each vial's own ratio. These are arithmetic consequences of the labels, not recommendations.
| If a draw contains… | From the 80 mg blend (5:1:1:1) | From the 25 mg blend (1:1:1:2) |
|---|---|---|
| 250 mcg BPC-157 | GHK-Cu 1,250 · TB-500 250 · KPV 250 mcg | GHK-Cu 250 · TB-500 250 · KPV 500 mcg |
| 500 mcg BPC-157 | GHK-Cu 2,500 · TB-500 500 · KPV 500 mcg | GHK-Cu 500 · TB-500 500 · KPV 1,000 mcg |
The same stated BPC-157 amount delivers five times as much GHK-Cu from one vial as from the other, and half as much KPV. Two vials both sold as a four-peptide healing blend are, in exposure terms, two different products.
Where the circulating figures come from, and why they do not fit
The figures attached to these blends are borrowed from the component compounds. This site has already sourced them one page at a time:
| Component | Commonly stated figure | Kind of source | Frequency |
|---|---|---|---|
| BPC-157 (dose record) | 250–500 mcg/day | Clinic and vendor pages, 2025–2026 | Daily |
| GHK-Cu (topical and injectable figures) | 1–2 mg/day injectable | Clinic, vendor and protocol pages | Daily to 3–7×/week |
| TB-500 (the fragment's page) | 2–2.5 mg twice weekly, then weekly | Community protocol pages | Twice weekly |
| KPV | No sourced origin for any figure | — | — |
Two mismatches follow. First, the frequencies disagree: the BPC-157 and GHK-Cu conventions are daily, the TB-500 convention is twice weekly, and a single vial cannot be drawn on two schedules at once. Second, the GHK-Cu convention is the one the 80 mg ratio happens to satisfy — a 250–500 mcg BPC-157 draw carries 1,250–2,500 mcg of GHK-Cu, which lands on the 1–2 mg figure. No seller page opened here says the ratio was designed for that, and we are not asserting it was; the arithmetic is simply consistent with it.
A "dosage guide" for the 80 mg blend, published in February 2026 by PeptideClinicLocator, states "200-500 mcg per injection, depending on specific peptide", then gives separate ranges for BPC-157 and TB-500 together and for KPV. In a premixed vial those are not four settings on one dial. They describe four different draws, each of which would deliver the other three peptides at whatever the ratio dictates.
What has been tested
Nothing, as a combination. The census on our stacks page ran every pairing of these components through ClinicalTrials.gov on 16 September 2026 and returned zero registered studies of any combination, against 3 registrations for BPC-157 alone, 1 for GHK-Cu and none for KPV. The registry search works; the combinations simply are not in it.
The component records are also uneven in kind. GHK-Cu has four human topical studies and no human study of an injection. TB-500 has no human study of the fragment at all. KPV has no registration and a literature dominated by delivery engineering. BPC-157's single human report is a retrospective series of 12 knee injections with no control group. A blend of four compounds does not average their evidence; it inherits every gap in all four.
What is not established
- No label, no monograph, no registered protocol for the blend, so no reviewed dose exists.
- No fixed composition. The name does not identify a product; two versions differ five-fold in GHK-Cu share.
- No stated reconstitution volume, so concentration is set after purchase.
- No published study of the combination, and no human injection study of GHK-Cu or any human study of TB-500 or KPV.
- No sterility or content guarantee from a purity figure. A purity percentage on a four-peptide vial speaks to detected material, not to the ratio being what the label says; our testing page sets out what each assay does and does not measure.
What a reader can check in ten minutes
- Open two sellers' KLOW pages and copy the milligram splits. Check whether they agree.
- Divide each component by the total to get the share. Note which peptide dominates.
- Search ClinicalTrials.gov for the four names together, then for each name alone.
- Ask any page quoting a blend dose which vial ratio the figure assumes.
- Check whether a reconstitution volume is stated anywhere on the product page.
Related on this site
The Wolverine stack dose record covers the two-peptide blend the same market sells, where the ratio is 1 : 1 and the frequency conflict is sharper. How to read a dosing claim sets out the questions that separate a label figure from a convention, and the peptide dosage chart indexes every dose record on this site by source type.
Sources and dates
Opened 17 September 2026: product pages at getprimelabs.com (KLOW 80 mg, composition and total peptide content), medicadepot.com (Klow, BPC-157 10 mg / GHK-Cu 50 mg / TB500 10 mg / KPV 10 mg), trueresearchlabs.com (KLOW blend, "80 MG" dosage option), simplepeptide.com (KLOW, 3 mL vial) and bhrcenter.com ("Quad Healing Blend", TB-500 5 mg / BPC-157 5 mg / KPV 10 mg / GHK-Cu 5 mg, 25 mg total); the PeptideClinicLocator dosage guide for the 80 mg blend, dated 17 February 2026. Component figures and registry counts are carried from this site's own sourced pages for BPC-157, GHK-Cu, TB-500 and KPV, and from the 16 September 2026 registry census on peptide stacks. Corrections go to the contact page.